I bet they'll fall back to same old funding argument, since there is no arguing that CTIX is continuing to load up the board with industry expertise. CTIX is hiring the right type of experts to push the next stages of drug and business development. I also wanted to comment on the fact that I think CTIX is going to make huge strides in the medical community now that Dr. Menon's time is available to push hard on the scientific end of things, as well as present at so many upcoming conferences. I have a feeling the remainder of this year will be peppered with steady and significant accomplishments, which will be mundane to the non-informed investor, but will build to a major catalyst (or two) early in 2017.